Literature DB >> 22622291

Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.

Xiaobin Wang1, Yunliang Chen, Xian Zhou, Fenghua Liu, Tao Zhang, Chunxiang Zhang.   

Abstract

BACKGROUND: Electroconvulsive therapy (ECT) is a preferred therapy for major depressive disorder. Intravenous propofol, a sedative and hypnotic agent, is one of the choices of anesthetic for ECT. Ketamine, another anesthetic agent, providing sedation, amnesia, and analgesia, can also be used in patients undergoing ECT owing to its rapid action and persistent antidepressive effect. One adverse effect of ketamine is cardiovascular excitement, which may be reduced by propofol. Currently, the effects of combined anesthesia (propofol and ketamine) for patients with depressive disorder who have undergone ECT are unclear. The purpose of this study was to investigate the effects of the combined agents for patients undergoing ECT.
METHODS: Forty-eight patients with Hamilton Depression Rating Scale (HDRS) scores greater than 20 were randomly divided into 3 groups (n=16 each): propofol group (group P), ketamine group (group K), and propofol plus ketamine group (group PK). Propofol (1.5 mg/kg), ketamine (0.8 mg/kg), and propofol (1.5 mg/kg) plus ketamine (0.8 mg/kg) were infused to each group of patients, respectively, before ECT by an anesthesiologist with no knowledge of the HDRS score. For the purpose of this study, the patients received a single ECT treatment and were assessed for depression using the HDRS scores (1 day before ECT and days 1, 2, 3, and 7 after the ECT treatment) by a psychiatrist with no knowledge of the randomization group. After the final assessment, the patients received further treatment as needed up to 3 treatments per week. Seizure energy index, seizure duration, and adverse effects were observed during anesthesia by a nurse with no knowledge of the study group.
RESULTS: The HDRS scores improved earlier in group K and group PK. Decreases in HDRS scores were significantly greater in group K and group PK compared with those in group P. The adverse effects in group PK were fewer than those in group K. Seizure energy index and seizure duration in group K and group PK were higher and longer than those in group P during ECT.
CONCLUSION: The results suggested that propofol combined with ketamine anesthesia might be the first-choice anesthesia in patients with depressive disorder undergoing ECT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622291     DOI: 10.1097/YCT.0b013e31824d1d02

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  45 in total

Review 1.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 2.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

3.  A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression.

Authors:  Shona L Ray-Griffith; Lou Ann Eads; Xiaotong Han; Kimberly Golden; Zachary N Stowe
Journal:  J ECT       Date:  2017-12       Impact factor: 3.635

4.  S -ketamine compared to etomidate during electroconvulsive therapy in major depression.

Authors:  Maxim Zavorotnyy; Ina Kluge; Kathrin Ahrens; Thomas Wohltmann; Benjamin Köhnlein; Patricia Dietsche; Udo Dannlowski; Tilo Kircher; Carsten Konrad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-19       Impact factor: 5.270

Review 5.  [Anesthesia for electroconvulsive therapy].

Authors:  U Grundmann; S O Schneider
Journal:  Anaesthesist       Date:  2013-04       Impact factor: 1.041

Review 6.  Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Authors:  Weili Zhu; Zengbo Ding; Yinan Zhang; Jie Shi; Kenji Hashimoto; Lin Lu
Journal:  Neurosci Bull       Date:  2016-11-22       Impact factor: 5.203

7.  Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study.

Authors:  Carolin Hoyer; Laura Kranaster; Christoph Janke; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-09       Impact factor: 5.270

8.  Effect of Ketamine, Thiopental and Ketamine-Thiopental Combination during Electroconvulsive Therapy for Depression.

Authors:  Özlem Özkan Kuşçu; Feride Karacaer; Ebru Biricik; Ersel Güleç; Lut Tamam; Yasemin Güneş
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-08-21

9.  Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy.

Authors:  Feray Erdil; Zekine Begeç; Gülay Erdoğan Kayhan; Saim Yoloğlu; Mehmet Özcan Ersoy; Mahmut Durmuş
Journal:  J Anesth       Date:  2014-08-02       Impact factor: 2.078

Review 10.  Ketamine administration in depressive disorders: a systematic review and meta-analysis.

Authors:  Guillaume Fond; Anderson Loundou; Corentin Rabu; Alexandra Macgregor; Christophe Lançon; Marie Brittner; Jean-Arthur Micoulaud-Franchi; Raphaelle Richieri; Philippe Courtet; Mocrane Abbar; Matthieu Roger; Marion Leboyer; Laurent Boyer
Journal:  Psychopharmacology (Berl)       Date:  2014-07-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.